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ABSTRACT: LmrCD is a lactococcal, heterodimeric multidrug transporter, which belongs to the ABC
superfamily. It consists of two half-transporters, LmrC and LmrD, that are necessary and sufficient for
drug extrusion and ATP hydrolysis. LmrCD is asymmetric in terms of the conservation of the functional
motifs of the nucleotide-binding domains (NBDs). Important residues of the nucleotide-binding site of
LmrC and the C loop of LmrD are not conserved. To investigate the functional importance of the LmrC
and LmrD subunits, the putative catalytic base residue adjacent to the Walker B motif of both NBDs
were substituted for the respective carboxamides. Our data demonstrate that Glu587 of LmrD is essential
for both drug transport and ATPase activity of the LmrCD heterodimer, whereas mutation of Asp495 of
LmrC has a less severe effect on the activity of the complex. Structural and/or functional asymmetry is
further demonstrated by differential labeling of both subunits by 8-azido-[R-32P]ATP, which, at 4 °C,
occurs predominantly at LmrC, while aluminiumfluoride (AlFx)-induced trapping of the hydrolyzed
nucleotide at 30 °C results in an almost exclusive labeling of LmrD. It is concluded that the LmrCD
heterodimer contains two structurally and functionally distinct NBDs.
The lactococcal heterodimeric multidrug transporter
LmrCD expels a range of drugs with diverse chemical
structures from the cell (1). It belongs to the ATP-binding
cassette (ABC)1 family and consists of two ABC half-
transporters, LmrC and LmrD, which are both composed of
a transmembrane domain with six transmembrane segments
(TMSs) and a carboxyl-terminal nucleotide-binding domain
(NBD). LmrCD is the first known ABC-multidrug resis-
tance (MDR) with a heterodimeric composition (1). Its drug
extrusion activity is strictly dependent upon the presence of
both subunits. The proteins have been isolated as a het-
erodimeric complex with a high basal ATPase activity (1).
Previous studies on ABC transporters have shown that the
NBDs bind and hydrolyze ATP and that the energy released
in this process drives the transport reaction. Sequence
conservation, crystallographic data, and biochemical studies
indicate that the NBDs of ABC transporters contain a series
of conserved motifs, such as Walker A and B and Q and H
motifs. These motifs of a single NBD form together with
the signature motif of the other NBD, a functional ATP
binding/hydrolysis site (reviewed in ref 2). Thus, dimerization
of the NBDs seems to be a critical step in the catalytic cycle.
Mutations in these motifs are often not tolerated and lead to
decreased transport and ATPase activities (3). Various
naturally occurring ABC transporters with partially degener-
ated motifs have been reported, for instance, the cystic
fibrosis transmembrane conductance regulator (CFTR) (4),
the yeast MDR Pdr5p (5), and the heterodimeric transporter
associated with the antigen-processing (TAP) complex (6).
Deviations from the functional motifs are often found in one
of the ATP-binding sites, whereas the other ATP-binding
site remains canonical.
The LmrC subunit of the heterodimeric LmrCD transporter
contains partially degenerated sequence motifs in its NBD.
Therefore, we have investigated the functional contributions
of both NBDs of the LmrCD heterodimer in drug transport.
Together with the histidine in the H loop (7), a conserved
glutamate following the Walker B motif has been postulated
to fulfill a critical catalytic role in the hydrolysis of ATP as
a catalytic base. This residue corresponds to Glu587 in LmrD
but, in LmrC, is substituted for an aspartate residue, i.e.,
Asp495. Both residues were mutated, and the effect thereof
on drug-transport activity and on ATP binding and hydrolysis
was determined. Our data provide strong evidence that
heterodimeric LmrCD contains two structurally and func-
tionally different nucleotide-binding sites.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions. Lactococcus
lactis NZ9000 (¢lmrA), which lacks the MDR transporter
LmrA (8), was used as host for expression from pNG8048E-
based plasmids, which contain a nisin-controlled promoter
(9). Cells were grown as described previously (10)t oa n
OD660 of 0.8 in M17 medium (Difco) supplemented with
0.5% (w/v) glucose and 5 íg/mL chloramphenicol.
Recombinant DNA Techniques. The plasmid pNSGA,
containing LmrC and LmrD behind a nisin-inducible pro-
moter and with an affinity tag localized on the C terminus
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Mutations were introduced by the overlapping PCR method
(11) and resulted in three different constructs, namely, LmrC/
LmrDE587Q, LmrCD495N/LmrD, and LmrCD495N/LmrDE587Q. All
cloned genes were verified by DNA sequencing.
Preparation of Membrane Vesicles. Inside-out membrane
vesicles were prepared from L. lactis NZ9000 (¢lmrA)
harboring different pNG8048E-based expression vectors.
Cells were grown at 30 °Cu pt oa nO D 660 of 0.8, and the
expressions of the plasmid-encoded genes were induced by
the addition of 0.2% (v/v) supernatant derived from an
overnight culture of the nisin-producing strain L. lactis
NZ9700 (12). Subsequently, cells were grown for 2 h,
harvested by centrifugation, and washed once with 50 mM
Tris-HCl at pH 7.0. Inside-out membrane vesicles were
derived from the cells as described previously (1). Membrane
vesicles were resuspended at a protein concentration of 40
mg/mL in 50 mM Tris-HCl at pH 7.0, supplemented with
10% glycerol and stored at -80 °C.
Strep-Tactin Affinity Purification. Inside-out membrane
vesicles (40 mg/mL total protein) containing overexpressed
wild-type or mutant LmrCD proteins were solubilized in 100
mM Tris-HCl at pH 8.0, 150 mM NaCl, 10% (v/v) glycerol,
and 1% (w/v) n-dodecyl-â-D-maltoside (DDM). After 30 min
of incubation on ice, the supernatant was subjected to a one-
step affinity purification on Strep-Tactin columns according
to the instructions of the manufacturer (IBA, Germany).
Purified proteins were visualized by SDS-PAGE and stained
with SYPRO Ruby Protein Stain Gel (Molecular Probes,
Inc.).
Transport Assays. L. lactis cells overexpressing wild-type
LmrCD or the various mutants were washed 3 times with
50 mM K-HEPES at pH 7.0 and 5 mM MgSO4. For transport
assays of 2¢,7¢-bis(2-carboxyethyl)-5,6-carboxylfluorescein-
acetoxymethyl ester (BCECF-AM), the washing buffer was
supplemented with 25 mM K2SO4. Cells were collected by
centrifugation and resuspended to an OD660 of 0.5 in the
buffer used for the fluorescence measurements. For ethidium-
transport measurements, cells were pre-energized for 5 min
with 20 mM glucose, whereupon ethidium was added to a
final concentration of 10 íM. The fluorescence of the
ethidium complex with polynucleotides was monitored at
excitation and emission wavelengths of 500 and 580 nm,
respectively (10). For BCECF-AM fluorescence measure-
ments, pre-energized cells were incubated with the iono-
phores valinomycin and nigericin (1 íM each) to preclude
any interference in the fluorescence measurements by the
transmembrane pH gradient. BCECF-AM was added to a
final concentration of 0.5 íM, and the fluorescence was
monitored at excitation and emission wavelengths of 502
and 525 nm, respectively (13). Hoechst 33342 (1 íM)
(Molecular Probes, Inc.) transport assays were performed
with glucose-energized cells. Fluorescence emission and
excitation wavelengths were 355 and 457 nm, respectively.
All measurements were performed at 30 °C with a Perkin-
Elmer Life Sciences model 50B fluorometer with a magneti-
cally stirred holder (10).
Hoechst 33342 Transport in Inside-Out Membrane Vesicles.
Hoechst 33342 (Molecular Probes, Inc.) becomes fluorescent
upon partitioning into the hydrophobic environment of the
cell membrane, while it is essentially nonfluorescent in
aqueous phase. This feature allows the monitoring of
movement of the drug between those two phases (14). Inside-
out membrane vesicles (1 mg of protein/mL) expressing wild-
type or mutant LmrC and LmrD proteins were incubated in
50 mM Tris-HCl at pH 7.0, 2 mM MgSO4, 8.5 mM NaCl,
0.1 mg/mL creatine kinase, and 5 mM phosphocreatine.
Subsequently, Hoechst 33342 was added to a final concen-
tration of 1 íM. The initial increase of fluorescence intensity
marks the partitioning of the drug into the lipid bilayer. After
stabilization of the fluorescent signal, 2 mM Mg-ATP was
added to initiate the Hoechst 33342 efflux. Fluorescence was
monitored as described in the previous section. Slit widths
were set to 3.5 nm.
ATPase Assay. The ATPase activities of purified LmrC
and LmrD were determined using the colorimetric method
of Lanzetta et al. (15). Purified proteins were incubated at
30 °C in a buffer containing 50 mM Tris-HCl at pH 7.4,
150 mM NH4Cl, 5 mM MgSO4, 15 mM MgCl2, 0.05%
(w/v) DDM, and 2.5 mM ATP. Every 10 min, aliquots
of 30 íL were transferred into wells of a 96-well micro-
plate and the reactions were terminated by the addition of
150 íL of malachite green molybdate reagent. After 5 min,
citric acid was added to a final concentration of 10% to
facilitate color development. Absorbance was measured after
at least 50 min of incubation at room temperature at 600
nm, and the ATPase activity was calibrated with phosphate
standards.
Growth Studies and Drug Inhibition. The sensitivity of
L. lactis cells overexpressing wild-type or mutant LmrCD
proteins to a variety of toxic compounds was studied in liquid
culture as described (16). Overnight cultures of L. lactis
NZ9000 (¢lmrA) harboring plasmids with wild-type or
mutant lmrCD genes were diluted into fresh medium and
grown further until the midexponentional growth phase. Cells
were diluted to an OD660 of 0.05, and 150 íL aliquots were
transferred to 96-well microtiter plates that contained growth
medium with the inducer (5 ng/mL nisin) and various
concentrations of the indicated drugs. The growth of cells
was monitored every 10 min for 16 h at 690 nm using a
multiscan photometer (Molecular Devices, Spectra Max 340).
Photoaffinity Labeling of LmrCD with 8-Azido-[R-32P]-
ATP. Purified and solubilized wild-type or mutant LmrCD
(0.2 íg of protein) were incubated for 5 min on ice with
0.5 íM 8-azido-[R-32P]ATP in the reaction buffer (50 mM
Tris-HCl at pH 8.0 with 20 mM MgSO4 and 0.05% DDM).
When indicated, MgSO4 was replaced for 20 mM EDTA,
or 3 íM to 12.5 mM of nonradioactive ATP was included
in the buffer. Subsequently, samples were irradiated with
UV (254 nm) for 5 min at 4 °C and analyzed by SDS-
PAGE, phosphoimaging, and quantisation. The competition
data was fitted to the Hill equation.
Aluminiumfluoride (ALFx)-Induced Trapping of the Posthy-
drolytic Nucleotide-Bound State of Wild-Type and Mutant
LmrCD. Similar to the binding reaction, the wild-type and
mutants of LmrCD were incubated in a reaction buffer with
0.5 íM 8-azido-[R-32P]ATP. To allow trapping of hydrolyzed
8-azido-[R-32P]ATP, proteins were incubated for 10 min at
30 °C in the presence or absence of 10 mM AlFx. AlFx was
prepared by mixing aluminum chloride and sodium fluoride
in a molar ratio of 1:100. The reaction was stopped by
transferring the samples on ice. Samples were UV-irradiated
at 254 nm for 5 min at 4 °C and analyzed by SDS-PAGE
and autoradiography.
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mined by Western blotting using poly(vinylidene difluor-
ide) (PVDF) membranes. Proteins were detected with
Strep-Tactin alkaline phosphatase conjugates directed against
Streptag II (IBA, Germany), visualized by chemilumines-
cence with CDP-Star (Roche Molecular Biochemicals), and
imaged on a Lumi Imager (Roche).
RESULTS
Site-Directed Mutagenesis of the NBDs of LmrCD. The
heterodimeric LmrCD contains partially degenerated se-
quence motifs in its NBDs. With ABC transporters, the
glutamate following the Walker B motif, a histidine in the
H loop, and the first glycine in the signature motif (2, 17)
are postulated to interact directly or via a water molecule,
with the ç phosphate of the bound nucleotide. These residues
are conserved in the NBD of LmrD that is believed to pair
with the conserved C loop of LmrC, thus forming a canonical
active site (Figure 1). On the other hand, the NBD site of
LmrC contains nonconserved residues and likely pairs the
nonconserved C loop of LmrD. It, therefore, appears that
the LmrCD heterodimer contains two structurally asymmetric
ATP-binding/hydrolysis sites (Figure 1).
To investigate the functional importance of LmrC and
LmrD, mutations that modify the charge of the putative
catalytic base residue adjacent to the Walker B motif were
introduced in the NBDs. This resulted in Asp495Asn and
Glu587Gln mutations in LmrC and LmrD, respectively.
Furthermore, mutated genes were combined to yield the
various heterodimeric complexes, i.e., wild-type LmrC/
LmrD, LmrC/LmrDE587Q, LmrCD495N/LmrD, and LmrCD495N/
LmrDE587Q. LmrD was tagged at its C terminus with a Strep
tag for visualization and purification. Attempts to tag LmrC
at the N terminus with either a Strep or a Hexa histidine tag
were unsuccessful (data not shown). Mutant and wild-type
LmrD could be overexpressed to high levels in L. lactis
(Figure 2). Only LmrD appeared to be expressed at a
somewhat lower level in the LmrC/LmrDE587Q and LmrCD495N/
LmrDE587Q mutants. Expression of LmrC was verified by
copurification with Strep-tagged LmrD (see Figure 5), as will
be detailed in the section on the ATPase activity.
Transport ActiVity of PutatiVe Catalytic Base Mutations
in LmrCD. LmrCD excretes a wide range of structurally and
functionally unrelated substrates (1). To investigate the
functional consequences of the introduced mutations, the
effects on transport of a set of fluorescent substrates were
examined. Ethidium is a dye that becomes fluorescent upon
binding to polynucleotides. In energized, control cells of L.
lactis NZ9000 (¢lmrA), the fluorescence of ethidium in-
creased steadily up to a saturation level (Figure 3A). In
contrast, in the presence of LmrCD, the ethidium fluores-
cence increased much more slowly in glucose-energized cells
(Figure 3A). This reduction in the ethidium fluorescence has
been attributed to the ability of LmrCD to prevent entry of
ethidium into the cells (1). On the other hand, energized cells
expressing the double-mutant LmrCD495N/LmrDE587Q were
unable to excrete the ethidium. Interestingly, the mutations
introduced in each of the monomers affected the transport
activity of the dimeric transporter differently. In L. lactis
expressing LmrCD495N/LmrD with the noncanonical aspartate
mutated in LmrC, the ethidium accumulation in energized
cells was almost the same as with wild-type LmrCD. This
FIGURE 1: Sequence alignment of ABC subunits of various ABC half-transporters. The Walker A, signature motif, Walker B, and the C-
and H-loop motifs are indicated in gray. The putative catalytic base is indicated in black.
FIGURE 2: Overexpression of wild-type and mutant LmrCD proteins
in L. lactis. Western blot of inside-out membrane vesicles, stained
with Strep-Tactin alkaline phosphatase directed against the affinity
tag engineered on the C terminus of LmrD. Lane 1, control vesicles;
lane 2, LmrCD; lane 3, LmrCD495N/LmrD; lane 4, LmrC/LmrDE587Q;
lane 5, LmrCD495N/LmrDE587Q. Overexpression was performed in
L. lactis NZ9000 (¢lmrA).
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transport activity. On the other hand, cells expressing LmrC/
LmrDE587Q had lost the transport activity of ethidium,
showing a similar level of ethidium accumulation as control
cells (Figure 3A).
To assess whether the effects of the mutations on the
transport activity of LmrCD is substrate-specific, transport
of two other LmrCD substrates, Hoechst 33342 and BCECF-
AM, was measured. When BCECF-AM enters the cells, it
is hydrolyzed by nonspecific intracellular esterases (18). The
intracellular release of BCECF results in an increase of
fluorescence. Because the fluorescence of BCECF is pH-
dependent, ionophores were used to equalize pH across the
cytoplasmic membrane to ensure that the fluorescence
increase is only due to intracellular BCECF-AM hydrolysis.
Energized cells overproducing LmrCD showed a reduced
influx of BCECF-AM compared to control cells, as evi-
denced by a slower increase of the BCECF fluorescence
(Figure 3B). In contrast, cells overexpressing the double-
mutant LmrCD495N/LmrDE587Q or LmrC/LmrDE587Q showed
under energized conditions an even higher fluorescence
increase than control cells. This implies that these mutant
proteins are no longer able to prevent entry of BCECF-AM
into the cell. BCECF-AM transport mediated by the
LmrCD495N/LmrD mutant was also reduced in comparison
to wild-type LmrCD but was still significantly higher than
in control cells (Figure 3B).
The third substrate of LmrCD tested was Hoechst 33342
(Figure 3C). Hoechst 33342 is a dye that becomes fluorescent
when it intercalates into the hydrophobic environment of the
cytoplasmic membrane or when it binds to DNA and RNA.
In comparison to control cells, the increase of Hoechst 33342
fluorescence was slow in energized cells expressing wild-
type LmrCD, consistent with the extrusion of this compound
from the cells. Energized cells overproducing the double-
mutant LmrCD495N/LmrDE587Q or LmrC/LmrDE587Q showed
even higher levels of Hoechst 33342 fluorescence as
compared to the control cells, indicating a greatly impaired
Hoechst efflux activity. The LmrCD495N/LmrD mutant showed
a significant, albeit reduced activity as compared to wild-
type LmrCD (Figure 3C). The transport data with three
different substrates collectively suggest an essential role of
glutamate 587 of LmrD in drug efflux, whereas the corre-
sponding aspartate 495 of LmrC appears to be of only
marginal importance.
LmrCD Mediated Hoechst 33342 Efflux in Membrane
Vesicles. To further examine the observed activities of the
wild-type and mutant LmrCD proteins, drug transport assays
were also performed with membrane vesicles (Figure 4). For
this purpose, Hoechst 33342 was used. In this assay, the
partitioning of Hoechst 33342 into the membrane is recorded,
and MDR activity is evident from a decrease in the
fluorescence upon energization of the transport system
because of a repartitioning of the Hoechst 33342 into the
buffer solution, wherein it is essentially nonfluorescent. Upon
energization with ATP, membrane vesicles containing either
overproduced LmrC or LmrD only showed minor extrusion
of Hoechst 33342 (Figure 4). In contrast, membrane vesicles
FIGURE 3: Transport studies in intact cells by wild-type and mutant
LmrCD. (A) Accumulation of ethidium by glucose-energized L.
lactis NZ9000 (¢lmrA) cells harboring the control plasmid
pNG8048E (EV) or plasmids expressing LmrC/LmrD, LmrCD495N/
LmrD, LmrC/LmrDE587Q, and LmrCD495N/LmrDE587Q. Washed cells
were pre-energized with glucose, whereupon ethidium bromide was
added to a final concentration of 10 íM. The fluorescence of
ethidium was monitored in time. (B) BCECF-AM transport in intact
cells by wild-type and mutant LmrCD. The formation of fluorescent
BCECF was followed in time as an indicator of the influx of
BCECF-AM into the cell. BCECF-AM (0.5 íM) was added to
glucose-energized cells of L. lactis NZ9000 (¢lmrA) harboring
various constructs. Cells were treated with the ionophores valino-
mycin and nigericin (1 íM each) to exclude any effects of the
transmembrane pH gradient on the BCECF fluorescence. (C)
Hoechst 33342 transport in intact cells by wild-type and mutant
LmrCD. The accumulation of Hoechst 33342 (1 íM) was followed
in time in glucose-energized cells of L. lactis NZ9000 (¢lmrA)
harboring various constructs.
FIGURE 4: Hoechst 33342 transport in inside-out membrane vesicles
by wild-type and mutant LmrCD. Hoechst 33342 (1 íM) was added
to inside-out membrane vesicles derived from L. lactis NZ9000
(¢lmrA) cells overexpressing LmrC/LmrD (line 1), LmrD (line 2),
LmrC (line 3), LmrCD495N/LmrD (line 4), LmrC/LmrDE587Q (line
5), LmrCD495N/LmrDE587Q (line 6), or containing the empty plasmid
(line 7). After 30 s, transport was started by the addition of 2 mM
Mg2+-ATP.
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a rapid fluorescence quenching of Hoechst 33342 upon
energization with ATP. On the other hand, the mutant
complexes, i.e., LmrCD495N/LmrDE587Q or LmrC/LmrDE587Q,
showed a greatly impaired rate of Hoechst 33342 efflux
(Figure 4). Surprisingly, unlike the energized whole cells,
membrane vesicles containing LmrCD495N/LmrD were sig-
nificantly reduced in Hoechst efflux activity.
ATPase ActiVity and LmrCD Heterodimer Formation.
LmrC copurifies with LmrD, demonstrating that these
proteins form a stable complex (1). Purified LmrCD exhibits
a high ATPase activity in the detergent-solubilized state,
whereas the individually purified LmrC or LmrD proteins
show minor ATPase activity (1). All three mutant complexes
could be copurified by using a Strep tag on LmrD (Figure
5A). However, recovery of the LmrCD complex containing
the LmrCD495N mutation was significantly lower than of the
wild-type complex (Figure 5A). Quantification of the inten-
sity of the individual subunits of the LmrCD495N/LmrD and
LmrCD495N/LmrDE587Q complexes by SYPRO Ruby staining
of the SDS-PAGE gels (data not shown) suggest that in
these mutants of the LmrC subunit are recovered with a lower
stoichiometry with LmrD as compared to the wild-type or
LmrC/LmrDE587Q complexes. It thus seems that the aspartate
mutation renders LmrC unstable.
The activity of the purified complexes was further studied
by determining their ATPase activities (Figure 5B). LmrC/
LmrDE587Q and double-mutant LmrCD495N/LmrDE587Q showed
no detectable ATPase activity, whereas a reduced but
significant ATPase activity was found with LmrCD495N/LmrD
(about 5% activity of the wild-type LmrCD) (Figure 5B).
The loss in ATPase activity is most likely related to the
reduced recovery of the latter complex as discussed above.
Our data demonstrate that mutagenesis of the aspartate 495
residue of LmrC mostly affects the stability of the complex,
whereas it still retains a significant but reduced ATPase in
Vitro and transport activity in ViVo. On the other hand,
mutagenesis of the glutamate 587 residue in LmrD resulted
in both a complete inactivation of the substrate transport and
ATPase activity.
8-Azido-[R-32P]ATP Binding to LmrCD. To determine if
both subunits of LmrCD bind nucleotides, cross-linking
studies were performed with the photoactivatable nucleotide
analogue 8-azido-[R-32P]ATP. For this purpose, purified
LmrCD was incubated in the presence of 8-azido-[R-32P]-
ATP, whereupon samples were illuminated with UV and
analyzed on SDS-PAGE. The protein content of the samples
was normalized for similar levels of LmrC. LmrC and LmrD
were labeled with different efficiencies by 8-azido-[R-32P]-
ATP (Figure 6A). Most of the label was recovered with
LmrC, which contains the nonconserved nucleotide-binding
site. The nucleotide-binding reaction is specific because it
could be competed by an excess of nonradioactive ATP and
strictly required Mg2+ ions (Figure 6A). The differences in
labeling could be due to differences in the reactive groups
in the binding site and/or nucleotide-binding affinity. An
estimate of the apparent ATP-binding affinity derived from
competition experiments of 8-azido-[R-32P]ATP labeling by
unlabeled ATP (Figure 6B) suggests that LmrD binds ATP
with a slightly higher affinity than LmrC, i.e., values of 4.4
and 7.2 íM, respectively (Figure 6C). These apparent Kd
values for MgATP are in the same range as reported for
Mdl1p (19). The mutant LmrCD complexes showed a similar
pattern of 8-azido-[R-32P]ATP labeling as the wild-type,
except for the LmrCD495N/LmrD mutant that was labeled to
a lesser extent in line with the observed instability of this
complex. These data demonstrate that the defective ATPase
activity of the mutants bearing the LmrDE587Q mutation is
not due to an impaired nucleotide-binding activity but is
caused by a catalytic defect.
AlF4-Induced Trapping of Azido-ADP by the ATPase
InactiVe Mutants of LmrCD. Inhibitors such as vanadate or
AlF4 are able to trap the bound nucleotides in ABC proteins
in a posthydrolytic state (20, 21). We have used these
trapping agents to determine if both nucleotide-binding sites
on LmrCD are capable of the hydrolysis of the â-ç bond
of ATP. Vanadate was found to be a poor trapping reagent
for the LmrCD, and therefore, this compound was not further
used for trapping experiments (data not shown). A similar
observation has been done for the TAP1/2 complex (21).
AlFx requires the hydrolysis of ATP to trap ATPases in a
transition state (21-23). The X-ray structures of the inhibited
FIGURE 5: Co-purification and ATPase activities of wild-type and
mutant LmrCD proteins. (A) SYPRO Ruby stained SDS-PAGE
of Streptag II affinity-purified protein from membranes derived from
L. lactis cells expressing LmrCD (lane 1), LmrCD495N/LmrD (lane
2), LmrC/LmrDE587Q (lane 3), and LmrCD495N/LmrDE587Q (lane 4).
The positions of LmrC and LmrD are indicated by arrows, and the
molecular-weight marker is presented in lane M. (B) ATPase
activity of the purified LmrCD (lane 1), LmrCD495N/LmrD (lane
2), LmrC/LmrDE587Q (lane 3), and LmrCD495N/LmrDE587Q (lane 4)
protein complexes.
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trapped state resembles the posthydrolytic state (24). Wild-
type and mutant LmrCD proteins were incubated for 10 min
at 30 °C with 8-azido-[R-32P]ATP in the absence and
presence of AlFx. The reaction was stopped on ice, and the
complex formation was analyzed by UV photocross-linking
and SDS-PAGE. The addition of AlFx resulted in strong
photolabeling of all tested proteins (Figure 7). Strikingly,
the trapped proteins showed a slower migration in SDS-
PAGE, which is either due to a different conformation or
caused by the presence of the bound AlFx. A low level of
photolabeling at 30 °C as in the previous experiments was
detected in the reactions in which the AlFx was omitted. The
latter reaction records the binding of 8-azido-[R-32P]ATP
only because it can be prevented by an excess of ATP when
added prior to the UV illumination, whereas an excess ATP
was ineffective when the complexes where trapped first in
the presence of AlFx and 8-azido-[R-32P]ATP. Despite the
lack of a detectable ATPase activity with the LmrC/
LmrDE587Q and LmrCD495N/LmrDE587Q mutants, strong pho-
tolabeling occurred after AlFx trapping, indicating the
hydrolysis of the â-ç phosphate bond of ATP (Figure 7).
Apparently, these mutants are still capable of ATP hydrolysis
but defective in a posthydrolysis reaction. The latter may
correspond to the release of bound ADP. Interestingly, under
the conditions employed, the photoaffinity label trapped with
AlFx preferentially localized at LmrD with the conserved
nucleotide-binding site, whereas LmrC is labeled only
slightly (Figure 7). Barely any label was found on the LmrC
subunit of the LmrCD495N/LmrD mutant, but this again may
be related to the instability of this mutant and the low level
of LmrC recovery when copurified with LmrD.
Effect of the Mutations on the LmrCD-Dependent Drug
Resistance in L. lactis. The effect of several toxic com-
pounds was investigated on the growth kinetics of L. lactis
overexpressing the wild-type or mutants of LmrCD. Cells
overexpressing the LmrCD495N/LmrD mutant complex showed
a similar drug resistance profile as cells overexpressing
wild-type LmrCD. In contrast, when LmrC/LmrDE587Q or
LmrCD495N/LmrDE587Q were overexpressed in L. lactis, cells
were found to be more sensitive to a range of drugs including
daunomycin, ethidium, and Hoechst 333342 (Table 1). These
in ViVo results confirm the notion that glutamate 587 of LmrD
is essential for drug efflux in contrast to the corresponding
aspartate 495 of LmrC.
DISCUSSION
LmrCD is a unique multiple drug ABC-type transporter
from L. lactis because it consists of two heterologous
FIGURE 6: Binding of 8-azido-[R-32P]ATP to the purified wild-
type and mutant LmrCD complexes. (A) 8-Azido-[R-32P]ATP
binding to wild-type and mutant LmrCD proteins. Proteins were
incubated for 5 min on ice with 8-azido-[R-32P]ATP in a buffer
containing 50 mM Tris-HCl at pH 8.0 and 0.05% DDM with 20
mM MgSO4 (lanes 2, 3, 5, 6, 8, 9, 11, and 12) or without MgSO4
but with 20 mM EDTA (lanes 4, 7, 10, and 13). To demonstrate
the specificity of the binding reaction, the radioactive probe was
mixed with an excess of nonlabeled 12.5 mM ATP (lanes 3, 6, 9,
and 12). Subsequently, samples were irradiated for 5 min with UV
light at 254 nm on ice and analyzed by SDS-PAGE and
autoradiography. (B) Competition of 8-azido-[R-32P]ATP binding
to wild-type LmrCD by ATP. Photocross-linking experiments with
0.5 íM 8-azido-[R-32P]ATP were in the presence of the indicated
concentration of ATP. (C) Quantitation of the inhibition of 8-azido-
[R-32P]ATP binding by ATP to LmrC (O) and LmrD (b).
FIGURE 7: AlFx-induced trapping of LmrCD-bound nucleotides.
Experimental conditions were as described in the caption of Figure
6, except for the incubation with 8-azido-[R-32P]ATP, which was
performed at 30 °C for 10 min in the presence (lanes 3, 5, 7, and
9) or absence (lanes 2, 4, 6, and 8) of AlFx.
Table 1: Drug Sensitivity of L. lactis (¢lmrA) Cells Expressing
Wild-Type and Mutant LmrCD Proteins
half-maximal inhibitory concentration (íM)a
drug
LmrC/
LmrD
LmrCD495N/
LmrD
LmrC/
LmrDE587Q
LmrCD495N/
LmrDE587Q
daunomycin 15.2 ( 2.5 9.6 ( 0.5 2.9 ( 0.3 2.5 ( 0.6
ethidium 0.74 ( 0.18 0.60 ( 0.14 0.41 ( 0.10 0.32 ( 0.11
Hoechst 33342 3.7 ( 0.5 2.2 ( 0.6 0.72 ( 0.01 0.64 ( 0.06
a IC50 values represent the average of at least two independent
experiments with the indicated standard error of the mean.
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its function (1). LmrCD can be purified as a stable het-
erodimeric complex that exhibits a high level of ATPase
activity. In contrast, the individual subunits are essentially
inactive. Here, we have conducted a mutational analysis of
LmrCD to address the question whether the NBDs of LmrC
and/or LmrD are essential for activity. Our data indicate that
the LmrCD heterodimeric complex contains two structurally
and functionally distinct ATP-binding/hydrolysis sites.
All ABC transporters known to date contain two NBDs
in their functional form. Crystallographic studies of iso-
lated NBDs (25-33) and the full-length transporters BtuCD
(34-36) and MsbA (37-40) reveal a common fold for the
NBD. The NBDs form an “ATP-sandwich” dimer, which
binds the ATP molecule(s) at the dimer interface of the
NBDs. Amino acid residues of conserved sequence motifs,
namely, Walker A and B and the Q and H loops donated by
one NBD, are complemented by the C loop from the opposite
NBD, thus forming a functional ATP hydrolytic site. Amino
acid substitutions in the conserved motifs usually lead to a
decreased transport and ATPase activity. Mutational analysis
has also revealed the requirement for intact and symmetrical
NBDs in terms of their functional motifs (17), but in several
heterodimeric ABC transporters, deviations in the consensus
sequences are tolerated, provided that these are restricted to
one of the ATP-binding or hydrolysis sites (17). NBDs
containing atypical sequence motifs were postulated to be
nonfunctional (41) or to have a regulatory function (2). In
the heterodimeric LmrCD complex, the NBDs are remark-
ably different in the amino acid sequence. Notably, the ATP-
binding site in LmrC is formed by the nonconserved
functional NBD motifs in LmrC and the degenerated C loop
from LmrD. The ATP-binding site in LmrD is canonical.
Structural analysis of various NBDs indicates that residues
that deviate from the consensus in the NBD of LmrC interact
with the ç phosphate of ATP. LmrC contains an aspartate
at the position that is usually occupied by a conserved
glutamate immediately following the Walker B motif. This
residue has been proposed to serve as a catalytic base that
coordinates the water molecule that attacks the ç phosphate
of bound ATP (reviewed in refs 42 and 43) or to play a role
in another critical step in the catalytic cycle (2). Furthermore,
in LmrC, a glutamine residue replaces the histidine of the H
loop that has been proposed to form a hydrogen bond with
ç phosphate (reviewed in ref 27). Finally, in LmrD, the first
glycine of the C loop, which is also involved in making
contacts with ç phosphate (22), is substituted by a valine.
Our results demonstrate that glutamate 587 in LmrD is
essential for ATP hydrolysis and drug extrusion. The
corresponding aspartate in LmrC at position 495 can be
mutated into an asparagine, and at least in ViVo, this mutation
does not inactivate the heterodimeric LmrCD complex,
although in Vitro studies indicate that the complex is severely
impaired in its activity.
Interestingly, although all LmrCD mutant complexes were
expressed to nearly similar levels, the amount of LmrCD495N
that could be copurified with Strep-tagged LmrD was
substantially lower than of the wild-type. The lower recovery
explains the reduced ATPase activity of the purified
LmrCD495N/LmrD complex and points at an instability of the
complex, which seems in particularly notable in Vitro.
Importantly, in intact cells, LmrCD495N/LmrD is almost as
active as the wild-type, while in inside-out membrane
vesicles, no significant transport activity of Hoechst 33342
was recorded. The purified LmrCD495N/LmrD showed a very
low ATPase activity, although the ATPase activity of the
complexes containing the LmrDE587Q mutant was completely
abolished. The nonessential role of aspartate 495 of LmrC
in drug resistance was also evident from in ViVo drug
sensitivity assays. L. lactis cells expressing the LmrCD495N/
LmrD complex were only slightly more susceptible to drugs
than cells expressing the wild-type LmrCD. On the other
hand, the LmrC/LmrDE587Q (or LmrCD495N/ LmrDE587Q)
mutant was unable to provide drug resistance to the cells.
When these data are taken together, they demonstrate that
asparatate 495 of LmrC does not play an essential catalytic
role, whereas glutamate 587 of LmrD is critical for the
function of LmrCD.
Strikingly, overexpression of the LmrC/LmrDE587Q or
LmrCD495N/LmrDE587Q complexes resulted in higher levels
of drug accumulation as compared to control cells under
energized conditions. We hypothesize that this phenomenon
is due to an inactivation of the endogenous levels of LmrCD,
which, when combined with excess LmrDE587Q, yields
inactive complexes. Indeed, overexpression of LmrDE587Q in
the absence of LmrC also resulted in a decreased drug efflux
activity of cells, while this phenomenon was not observed
when LmrC/LmrDE587Q or LmrCD495N/LmrDE587Q was over-
expressed in a L. lactis ¢lmrCD strain (unpublished data).
To elucidate whether the decreased or complete loss of
steady-state ATPase activity of the mutant LmrCD com-
plexes was due to inefficient binding of the nucleotide,
8-azido-[R-32P]ATP cross-linking experiments were con-
ducted. All mutants showed similar levels of binding at 4
°C as the wild-type, except for the LmrCD495N/LmrD mutant.
The latter may be due to a reduced ATP-binding affinity
but is more likely caused by the instability of this mutant as
discussed above. Likewise, the mutation of the putative
catalytic base in the human P-glycoprotein (42), mouse Mdr3
(44), and the MRP 1 does not abolished labeling by 8-azido-
[R-32P]ATP (44-46). Interestingly, we observed an asym-
metric labeling with 8-azido-[R-32P]ATP. Most of the
detected label localizes to LmrC, whereas the binding studies
suggest that LmrD binds the nucleotide with a slightly greater
affinity than LmrC. Asymmetric labeling has also been
demonstrated for the nonequivalent NBDs of MRP1 (21) and
the subunits of the TAP complex (21, 42). The difference in
labeling of the two NBDs presumably relates to differ-
ences in the chemical reactivity of both sites for 8-azido-
[R-32P]ATP. Importantly, in the presence of AlFx to trap an
Mg-ADP-AlFx complex, labeling strongly increased and
occurred predominantly at LmrD, which contains the con-
served nucleotide-binding motifs. On the other hand, labeling
of LmrC was increased to a much lesser extent. Strikingly,
in the presence of AlFx, LmrD was also strongly labeled with
the instable LmrCD495N/LmrD mutant. AlFx traps ATPases
in the transition state following hydrolysis of ATP (44-47).
Thus, the increased labeling efficiency of LmrD suggests
that this site is the primary catalytic site. The different levels
of labeling demonstrate that both NBDs are structurally and
functionally dissimilar. Asymmetrical trapping of a transition
state with vanadate has also been observed with the non-
equivalent NBDs of MRP1 (20, 48). However, with the
human P-glycoprotein, which contains canonical NBDs,
654 Biochemistry, Vol. 45, No. 2, 2006 Lubelski et al.vanadate-trapping occurred equally effective at the N- and
C-terminal NBD (49), although differential labeling has been
reported as well (25, 50). Because the binding of the
nucleotide by the LmrCD complexes bearing the LmrDE587Q
mutation can be trapped by AlFx, it appears that this residue
is not essential for hydrolysis of the â-ç phosphate bond
of ATP per se. The glutamate mutant is, however, defective
in steady-state ATP hydrolysis, indicating that it is most
likely perturbed in a posthydrolytic step. This further raises
the question on the functional significance of the glutamate
as a catalytic base in ABC transporters. Structural analysis
of the NBDs of various ABC transporters indicates that the
glutamate is well-positioned for a hydrolytic attack of the ç
phosphate of ATP (50). Another closely spaced and con-
served residue, histidine was proposed to function as a
ç-phosphate sensor (51). Mutation of the glutamate into a
glutamine in HisP (52) and BmrA (53) resulted in a defective
ATPase activity but an unaltered binding of ATP. The so-
called E-Q mutant of BrmA showed a vanadate insensitive
trapping of the triphosphate state of a radioactive AT(D)P
analogue, in line with the hypothesis that the glutamate acts
as a catalytic base in BmrA. In contrast, with mouse P-gly-
coprotein (Mdr3), the same mutation yielded vanadate-
trapped ADP in the NBD (22). However, the rate of MgADP
release was not affected in this mutant (7), and it was
suggested that the glutamate is needed to complete the
catalytic cycle. A recent structural and kinetic study on HlyB
suggests that the conserved glutamate acts together with the
histidine from the H loop to form a catalytic dyad, which
functions in substrate-assisted catalysis. In this mechanism,
the histidine appears to function as a catalytic base, while
glutamate 631 is needed to orient the histidine for the
hydrolytic attack of the â-ç phosphate bond. A crucial role
of the histidine as the true catalytic base would also explain
our observations with the LmrDE587Q mutant, which still
supports an AlFx-induced trap of bound nucleotide, indicative
of a retained ability to hydrolyze the â-ç phosphate bond
of the bound nucleotide.
When our results are taken together, they suggest that the
sequence asymmetry of the conserved motifs in the NBDs
of LmrC and LmrD results in functional nonequivalency of
the NBDs. Structurally, both NBDs appear indispensable,
while functionally, they seem to fulfill different roles in
nucleotide hydrolysis as suggested by the AlFx-trapping
experiments. These observations raise intriguing questions
as to how many ATP molecules are needed for transport of
one substrate by this ABC transporter. Possibly, two ATP
molecules bind to LmrCD, but rapid hydrolysis of only one
ATP may be needed during a turnover.
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